Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, She D, Cimbora D, Pittock SJ, Weinshenker BG, Paul F, Marignier R, Wingerchuk D, Cutter G, Green A, Hartung HP, Kim HJ, Fujihara K, Levy M, Katz E, Cree BAC; N-MOmentum study investigators.
Bennett JL, et al. Among authors: smith ma.
EBioMedicine. 2022 Dec;86:104321. doi: 10.1016/j.ebiom.2022.104321. Epub 2022 Nov 10.
EBioMedicine. 2022.
PMID: 36370634
Free PMC article.
Clinical Trial.
All participants receiving inebilizumab demonstrated a robust long-term therapeutic response, and participants with 4 cells/muL after the first 6-month dosing interval had persistently deeper B-cell depletion, lower annualised attack rates (estimated rate [95% CI]: 0.034 [ …
All participants receiving inebilizumab demonstrated a robust long-term therapeutic response, and participants with 4 cells/muL after …